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Abstract
To evaluate the significance of interleukin 4 (IL-4) in tumor development, we
compared B16F10 melanoma growth in IL-4-overespressing transgenic mice (IL-4
mice) and non-transgenic mice. In IL-4 mice, reduced tumor volume and weight were
observed when compared with those of non-transgenic mice. Significant activation
of DNA binding activity of STAT6, phosphorylation of STAT6 as well as IL-4, IL-4Rα
and p21 expression were found in the tumor tissues of IL-4 mice compared to nontransgenic mice. Higher expression of IL-4, STAT6 and p21 in human melanoma
tissue compared to normal human skin tissue was also found. Higher expression of
apoptotic protein such as cleaved caspase-3, cleaved caspase-8, cleaved caspase-9,
Bax, p53 and p21, but lower expression levels of survival protein such as Bcl-2 were
found in the tumor of IL-4 mice. In vitro study, we found that overexpression of
IL-4 significantly inhibited SK-MEL-28 human melanoma cell and B16F10 murine
melanoma cell growth via p21-mediated activation of STAT6 pathway as well as
increased expression of apoptotic cell death proteins. Moreover, p21 knockdown
with siRNA abolished IL-4 induced activation of STAT6 and expression of p53 and
p21 accompanied with reduced IL-4 expression as well as melanoma cell growth
inhibition. Therefore, these results showed that IL-4 overexpression suppressed
tumor development through p21-mediated activation of STAT6 pathways in melanoma
models.

Introduction

expressed in solid tumors and non-hematopoietic cells [1].
Human tumor cell lines including expressing IL-4R has
been shown to mediate anti-proliferative activity of IL-4
[2–4]. It is noteworthy that cytokines released in response
to infection, inflammation and immunity can function to
inhibit tumor development and progression [5]. IL-4 is a
pleiotropic type cytokine produced primarily by CD4+ T
cells. [6, 7]. IL-4 has an inhibitory role in angiogenesis [8],

Interleukin-4 (IL-4) is a multifunctional cytokine
that plays a critical role in the regulation of immune
responses. The IL-4Rs are divided with type I IL-4R
consisting IL-4Ra and the common gamma chain (γc),
and type II consisting IL-4Rα and IL-13Rα1. Type I
IL-4R is expressed in lymphocytes and type II IL-4R is
www.impactjournals.com/oncotarget
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The STAT signaling pathway appears to negatively
regulate the cell cycle by inducing CDK inhibitors p21
in response to IFN-γ in A431 human epithelial carcinoma
cells [31]. Thrombin inhibits cell growth by both upregulation of STAT1 dependent p21waf/cip1 and induction
of caspases via its PAR-1 receptor in DU145 prostate
cancer cells [32]. However, effect of IL-4 on STAT6 and
p21 dependent cell cycle arrest has not been studied.
Malignant melanoma is a common primary malignant
cutaneous tumor derived from transformed epidermal
melanocytes [33]. The incidence of cutaneous melanoma has
more than doubled over the last decades making it one of
the fastest rising cancers worldwide [34]. Many possible
mechanisms and target therapeutics for melanoma treatment
have been demonstrated but clear cut mechanisms and
therapeutics have not been reported. Therefore, in the present
study, to evaluate the role of IL-4 in skin tumor growth,
we investigated whether overexpression of IL-4 inhibits
melanoma cell and tumor growth through modulation of
p21-mediated STAT6 pathways.

as well as in cancer growth, such as multiple monocyte
[9], lung [10], kidney [11], liver [12], breast [13]. IL-4
transfection of cDNAs into mouse melanoma cells
decreased the tumorigenicity of B16F10 melanoma cells
by the activation of immune response [14].
A variety of important cellular functions are
regulated by cytokines. The Janus kinase (JAK)-signal
transducer of activators of transcription (STAT) pathway is
now recognized as an evolutionarily conserved signaling
pathway employed by diverse cytokines, interferons,
growth factors, and related molecules [15]. Following
binding of a ligand to its cognate receptor, receptorassociated Jaks are activated. STAT proteins are then in
turn activated by tyrosine phosphorylation by Jak kinases,
allowing their dimerization and subsequent translocation
into the nucleus, where they modulate expression of
target genes [16]. STAT proteins are critical mediators
of cytokine signaling. Compared with normal cells and
tissues, constitutively activated STATs have been detected
in a wide variety of human cancer cell lines and primary
tumors including a melanoma skin cancer. Numerous
studies have demonstrated constitutive activation of STATs
in particular STAT1, STAT3 and STAT5 by cytokines in a
large number of diverse human tumor cell lines [17, 18].
STAT6 is activated by IL-4 and IL-13, and plays a
predominant role in oncogenesis. IL-4 induces apoptosis
of human hepatocytes through STAT6 activation, and
increased caspase activation [12]. IL-13 also induces
STAT6 dependent apoptosis in HT-29 colon cancer cells
[19]. IL-12 activates STAT4 and enhances antitumor
activity through IFN-γ production. IL-27 activates STAT1
and enhances antitumor activity [20]. However, the
relationship between melanoma skin cancer and activation
of STAT6 has not yet been studied.
The cyclin-dependent kinase inhibitor p21
(also known as p21WAF1/Cip1) promotes cell cycle arrest
in response to many stimuli. It is well positioned to
function as both a sensor and an effector of multiple antiproliferative signals [21]. Expression of p21 induced
apoptosis in prostate [22], skin [23], and thyroid cancer
cells [24] as well as melanoma [25]. It is reported that
expression of p21 is increased in human malignant
melanoma tissues compared to normal tissue [26].
Expression of p21 is also associated with p53 and
proliferating cell nuclear antigen (PCNA) expression level
in clinical stage I cutaneous malignant melanoma patients
[27]. Its expression is usually induced by p53 protein after
DNA damage, and it has a role in inhibiting several cyclin
dependent kinases (CDK2, CDK3, CDK4 and CDK6)
resulting in G1 cell cycle arrest and block of transition
in S phase [28]. p21 is also able to determine cell cycle
arrest in G2 phase, through its interaction with PCNA, an
essential cofactor for DNA polymerases [29]. Recently,
it was reported that STATs protein and p21 protein are
associated during apoptosis. STAT1 protein is essential
for cell growth suppression in response to IFN-γ [30].
www.impactjournals.com/oncotarget

RESULTS
Effect of IL-4 on cancer cell growth and
apoptotic cell death
The expression of IL-4Rα mediates the action
of IL-4, so we performed the Western blot analysis to
investigate the IL-4Rα expression of various cancer cells
(Figure 1A). The highest expression of IL-4 and IL-4Rα
was found in melanoma cells among the cancer cells
(Figure 1A). We then analyzed cell growth by MTT assay.
A549, NCI-H460, SW 480, HCT 116, Caki-1, SN12C, Ca
Ski, C33A, MCF-7 and MDA-MB 231 cells were treated
with IL-4 (50 ng/ml) for 24 hr. IL-4 inhibited cell growth
of these cancer cells, and the most inhibition was found
in melanoma (Supplementary Figure 1). The growth
inhibition was associated with IL-4 and IL-4Rα expression
(Figure 1A). Since IL-4 and IL-4Rα were highly expressed
in melanoma cells, and melanoma cell growth has been
known to be significantly affected by cytokines [35],
we chose melanoma cells for further mechanism and
in vivo studies to investigate the role of IL-4 in melanoma
growth. SK-MEL-28 and B16F10 cells were treated with
several concentrations of IL-4 (10, 25 and 50 ng/ml)
for 24 hr, and found cell growth inhibition in a dose
dependent manner (Figure 1B, 1C). We then performed
DAPI staining followed by TUNEL staining assays. The
double labeled cells were analyzed by a fluorescence
microscope to determine that the inhibition of cell growth
by IL-4 was due to the induction of apoptotic cell death.
Reversely, consistent with cell growth inhibitor effects,
apoptotic cell death was significantly increased in rhIL-4
treated B16F10 melanoma cells, respectively. The number
of apoptotic cells (DAPI-positive TUNEL-stained cells)
in B16F10 melanoma cell culture was increased to about
23426
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58 % of cells, respectively, at a concentration of 50 ng/ml
(Figure 1D, 1E).

proteins; Bax and cleaved form of caspase-3, -8, -9
were increased by the treatment of IL-4. However, the
expression of Bcl2 was decreased by the treatment of IL-4
in SK-MEL-28 (Figure 2A) and B16F10 melanoma cells
(Figure 2B).

Effect of IL-4 on expression apoptotic cell death
regulation proteins

Effect of IL-4 on STAT6 activation and
expression of p21

The activation of cell death regulatory proteins
including caspases-3, -8 and -9 as well as Bax, leads to
apoptosis in cancer cells. To determine the association of
the expression of cell death regulatory proteins and IL-4,
the expression of apoptotic proteins was investigated
by Western blots. IL-4 treatment clearly increased IL-4
and IL-4Rα expression. Consistent with increased IL-4,
and IL-4Rα expression, the expression of pro-apoptotic

To investigate whether IL-4 activates STAT6
activation, an EMSA for detecting DNA binding activity
of STAT6 was carried out. We found that IL-4 untreated
SK-MEL-28 and B16F10 melanoma cells showed lower
constituted activation of STAT6 in SK-MEL-28 and

Figure 1: Effect of IL-4 on cancer cell growth and apoptotic cell death. Expression of IL-4Rα in various cancer cell line
including B16F10 melanoma cells (A). Concentration-dependent effect of IL-4 on the MTT viability assay in SK-MEL-28 and B16F10
after 24 hr (B and C). The B16F10 melanoma cells were treated with IL-4 for 24 hr, and then labeled with DAPI and TUNEL solution (D).
Total number of cells in a given area was determined by using DAPI nuclear staining (fluorescent microscope). The green color in the
fixed cells marks TUNEL-labeled cells. The apoptotic index was determined as the DAPI-stained TUNEL-positive cell number/total DAPI
stained cell number (magnification, 200×) (E). Values were means ± S.D. of three experiments. * (P < 0.05) indicates statistically significant
differences from the control cells.

www.impactjournals.com/oncotarget
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B16F10 melanoma cells. However, the treatment IL-4 dose
dependently increased DNA binding activity of STAT6.
Agreed with the increment of DNA binding activity of
STAT6, the phosphorylation of STAT6 in nuclei was
increased by IL-4 treatment in SK-MEL-28 (Figure 3A)
and B16F10 melanoma cells (Figure 3B). The band of
STAT6 was supershifted by STAT6 specific antibody in
SK-MEL-28 melanoma cells (Supplementary Figure 2).
Expression of p21 is associated with apoptotic cell death
and growth arrest of cancer cells in conjunction with
STAT6 activity. Therefore, to investigate expression of
p21 in SK-MEL-28 human melanoma cell and B16F10
murine melanoma cell undergoing apoptotic cell death, we
performed a Western blot analysis. IL-4 treatment clearly
increased expression of p21 in a dose dependent manner
(Figure 3C, 3D). We also demonstrated p21 activity by an
immunofluorescence analysis by a confocal microscope.
SK-MEL-28 and B16F10 cells were treated with IL-4
(0–50 ng/ml) for 24 h. Translocation of p21 into the

nucleus was also increased significantly in a dose
dependent manner (Figure 3E, 3F).

Reversed effect of p21 siRNA on IL-4-induced
cell growth inhibition and STAT6 activation
To determine the relationship between p21
expression and SK-MEL-28 and B16F10 melanoma cells
growth and STAT6 activity in the inhibitory effects of IL-4,
we transfected SK-MEL-28 and B16F10 melanoma cells
with p21 siRNA using a transfection agent. The melanoma
cells were transfected with 100 nM siRNA of p21 for 24
hr, and then treated with IL-4 (50 ng/ml) for 24 hr. Knock
down of p21 almost completely reversed the cell growth
inhibitory effect of IL-4 in SK-MEL-28 (Figure 4A)
and B16F10 cells (Figure 4B). We also found that
expression of IL-4, IL-4Rα, p53 and p21 was also reversed
(Figure 4C, 4D). IL-4-increased activity of STAT6 by IL-4
was also abolished by transfection with p21 siRNA in

Figure 2: Effect of IL-4 on expression of apoptotic cell death regulation proteins. Western blot analysis with the antibodies
against IL-4, IL-4Rα, Jak1 and p-Jak1 and apoptosis regulatory proteins including p53, Caspase-3, caspase-8, caspase-9, Bax, Bcl-2 and
β-actin (A and B). β-actin protein was used an internal control. Each band is representative for three experiments.
www.impactjournals.com/oncotarget
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SK-MEL-28 and B16F10 melanoma cells (Figure 4E, 4F).
Increased nucleus phosphorylation of STAT6 by IL-4 was
also abolished by transfection with p21 siRNA in SKMEL-28 and B16F10 melanoma cells (Figure 4G, 4H).

group, expressions of IL-4, IL-4Rα, phosphorylation
of Jak1 and pro-apoptotic proteins including cleavage
caspase-3 were concomitantly increased (Figure 5C).
Immunohistochemical analysis showed that the number of
IL-4 immunoreactive cells was higher in the tumor tissues
of IL-4 mice (Figure 5D). We also found higher binding
activity of STAT6 in B16F10 bearing IL-4 mice compared
to non-transgenic mice. Agreed with the increment of
STAT6 and cytosolic phosphorylation of STAT6, as well
as the nucleus phosphorylation of STAT6, were increased
(Figure 5E).

IL-4 inhibited tumor growth in melanoma model
To identify the effect of IL-4 on tumor growth,
we measured the tumor growth in a melanoma model.
We conducted in vivo study after confirmation higher
expression of IL-4 in serum of Luc/IL-4/CNS-1mice
compared to Non-Tg mice (Supplementary Figure 3).
The results revealed that tumor volume and weight in
B16F10 bearing IL-4 mice were much lower compared
to non- transgenic mice. Tumor growth in IL-4 mice
was less than the tumor growth in non-transgenic mice
(Figure 5A). Expression of PCNA was decreased in
IL-4 mice (Figure 5B). In the B16F10 bearing IL-4 mice

Expression of IL-4, STAT6 and p21 in human
melanoma patient tissue
We analyzed expression of IL-4, STAT6 and p21 in
human melanoma tissues (Stage II–IV) and normal tissues
by immunohistochemistry analysis. IL-4, STAT6 and p21

Figure 3: Effect of IL-4 on STAT6 activation and expression of p21. Nuclear extract from melanoma cells treated with IL-4
(10, 25, and 50 ng/ml) for 1 hr was incubated in binding interaction of 32P-end-labeled oligonucleotide containing the STAT6 sequence. The
present EMSA results are representatives of three experiments. The cells treated with IL-4 for 1 hr was incubated and were lysed, nuclear
proteins were used to determine the expression of STAT6, p-STAT6 and Histone (internal control) in SK-MEL-28 human melanoma cells
and B16F10 murine melanoma cells (A and B). Western blot analysis with antibodies against p21 and β-actin (C and D). β-actin protein
was used an internal control. Each band is representative for three experiments. Melanoma cells were treated with 10 to 50 ng/mL IL-4
for 24 h, and then the intracellular location of p21 was determined by immunofluorescence confocal scanning microscope (magnification,
630×). Double staining (Merge) with p21 and 4′, 6-diamidino-2-phenylindole (DAPI) staining shows the localization of p21 in the nucleus
(E and F).
www.impactjournals.com/oncotarget
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are concomitantly and progressively expressed in human
melanoma tissues in a cancer stage dependent manner
(Figure 6).

has been contingently approved for the treatment
of patients with advanced melanoma based on their
durable response, high response rate, and favorable
safety profile [37]. Pembrolizumab is a highly selective
humanized monoclonal IgG4 antibody directed against
the programmed death-1 (PD-1) receptor on the cell
surface [38]. PIs (bortezomib, ALLN, MG-132 and
epoxomicin) triggered apoptosis in melanoma cell lines
accompanied by cytochrome C release, activation of
multiple caspases and by significant increase in number
of treated melanoma cells in sub-G1 phase of cell cycle
[39]. Although these therapeutic treatments have achieved
significant benefits for patients in clinical trials, its
effectiveness and administration have been limited by
toxic side effects. The most frequent side effect (incidence
> 30%) associated with bortezomib in clinical trials include
asthenic conditions, gastrointestinal events, hematological
toxicity, peripheral neuropathy characterized by decreased

DISCUSSION
Potential anti-melanoma drugs, including antiangiogenic agents, kinase inhibitors, non-antisense
oligonucleotides and proteasome inhibitors (PI) are
currently in clinical trials. It has been proposed that
the resistance of metastatic melanoma to traditional
chemotherapeutic and new anticancer agents is mainly
due to the increased resistance of melanoma cells to druginduced apoptosis [36]. Metastatic melanoma patients are
often treated with one of several targeted therapies approved
by the Food and Drug Administration (FDA),
including vemurafenib (Zelboraf®), dabrafenib (Tafinlar®)
and trametinib (Mekinist®). Recently, pembrolizumab

Figure 4: Reversed effect of p21 siRNA on IL-4-induced cell growth inhibition and STAT6 activation. The melanoma cells
were transfected with the p21 siRNA (100 nM) for 24 hr, the cells were then treated with IL-4 (50 ng/ml) for 24 hr. After treatment, cell
viability was measured by MTT assay (A and B), and the expression of apoptosis regulatory proteins (C and D) and STAT6 activity (E and F)
were determined as described above. Cell growths are means ± S.D. of three experiments. * (P < 0.05) indicates statistically significant
differences from control group. # (P < 0.05) indicates statically significant differences from rhIL-4 treated group.
www.impactjournals.com/oncotarget
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sensation, paresthesia and a high rate of shingles [40, 41].
Spontaneous regressions of malignant melanoma
lesions have been observed via activated lymphocytes
[42]. Indeed, infiltration of T cells within melanoma
tumors can be associated with a better prognosis [43].
Thus, modulation of immune responses by the use of
recombinant cytokines or cytokine is one of the strategies
for cancer therapy to reduce side effects [44].
In the present study, we found that IL-4
overexpression inhibited cell growth of cultured
SK-MEL-28 human melanoma cells and B16F10 murine
melanoma cells in vivo through p21-mediated activation
of STAT6. IL-4 has an inhibitory role in angiogenesis [8],
as well as in cancer growth such as multiple monocyte
[9], lung [10], kidney [11], liver [12], and breast [13]
cancer cells. Human tumor cell lines expressing IL-4R
has been shown to mediate anti-proliferative activity of

IL-4 [2, 4, 45]. To see whether IL-4R expression could be
related to an anti-cancer effect of IL-4, we investigated
the IL-4R expression pattern in several cancer cell lines.
Expression of IL-4Rα on melanoma cell lines was higher
than other cancer cell lines, which was associated with
higher cancer cell growth inhibition and apoptotic cell
growth. IL-4 down-regulated the surface expression of
IL-4Rα on one human renal cancer cells, gastric cancer
cells and breast cancer cells [46–48], and thus showed
much higher cell growth-inhibitory effects of IL-4 than
IL-4R non expressed cells [46–48]. Other cytokine
receptors have been shown to mediate the anti-cancer effect
of their cytokines. IL-13Ra2 has a critical role to mediate
the anti-tumor effect of IL-13 in breast cancer models [49].
IL-15Rα also mediates the anti-tumor effect of IL-15 in
a B16 melanoma mouse model. [50]. IL-12R triggers the
anti-tumor effect of IL-12 in ovarian cancer [51]. These

Figure 5: IL-4 inhibited tumor growth in melanoma model. Tumor growth inhibition (as assessed by tumor volume) in B16F10
bearing IL-4 mice. Tumor burden was measured twice per week using a caliper, and volume was calculated with volume length (mm)
× width (mm) × height (mm)/2. Tumor weight and volume are presented as means ± S.D. (A). Immunohistochemistry was used to determine
expression levels of PCNA in tissues of IL-4 mice and non-transgenic mice (B). The expression of IL-4 and apoptotic proteins was detected
by western blotting using specific antibodies; IL-4, IL-4Rα, Jak1, p-Jak1, cleaved caspase-3, Bcl-2 and β-actin (C). β-actin protein was
used an internal control. Tumor sections were analyzed by immunohistochemistry for detection of IL-4 expression in tumor tissues (D).
STAT6 activity in tumor tissues was detected by EMSA and nuclear location of STAT6 was determined by western blotting. (E). All values
represent mean ± SD from five animal tumor sections. * (P < 0.05) indicates significan.tly different from the control group.
www.impactjournals.com/oncotarget
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data suggest that IL-4 could suppress melanoma cell
growth via receptor-mediated cell death effect.
Activation of the p21 pathway of growth arrest
and apoptosis is a well known signaling pathway in
the regulation of melanoma cell growth. Keratinocyte
derived from p21−/− mice results in a markedly increased
susceptibility to 7, 12-dimethylbenzanthracene (DMBA)
induced skin carcinoma formation [52]. Moreover, p21
are concomitantly and progressively expressed in human
melanoma tissues in a cancer stage dependent manner. It
is also reported that expression of p21 in human tumor
tissue is increased in gastric [53], laryngeal [54] cancer
cells as well as melanoma [26]. It is reported that all trans
retinoic acid (atRA) induce apoptosis in WM164 primary
melanoma cells and 451Lu metastatic melanoma cells.
Expression of p53, p21 and bax was increased, and bcl-2
was decreased in melanoma cells after exposure to atRA
at different concentrations for various periods of time [25].
Thus, the cyclin-dependent kinase inhibitor p21 promotes
cell cycle arrest in response to many stimuli. It is well
positioned to function as both a sensor and an effector of

multiple anti-proliferative signals. In our data, inhibition
of melanoma cell growth by rhIL-4 accompanied
increased expression of p21 in a dose dependent manner.
But, inhibition of cell growth by higher expression of
p21 response to IL-4 was abolished by transfection with
p21 siRNA in SK-MEL-28 and B16F10 melanoma cells.
Expression of p21 was also increased in the tumor of
IL-4 mice compared with those of non-transgenic mice.
Cell-cycle regulation in mammalian cells is affected by
the ordered activation of a group of related enzymes
known as the cyclin-dependent kinase (CDK) [55]. p21
as a CDK inhibitor is a key cell cycle regulator that
arrests cells in the G1 and G2 phases [56]. Our present
results showed that expression of IL-4 and IL-4Rα in SKMEL-28 and B16F10 melanoma cells were increased.
However, treatment of p21 siRNA in SK-MEL-28 and
B16F10 reversed IL-4-induced melanoma cancer cell
growth inhibition. It was reported that many cytokines
arrest cancer cell cycle through activation of p21 in 5637
and T-24 bladder cancer cells [57]. IFN-α increases the
expression of p21 in a carcinoid tumor cell line, and thus

Figure 6: Expression of IL-4, STAT6 and p21 in human melanoma patients. Human normal skin or melanoma tissue sections
(Stage II–IV) were processed and stained with H & E and immunohistochemistry analysis of the expression of IL-4, STAT6 and p21. The
figures represented 3 samples of each cancer stage.
www.impactjournals.com/oncotarget
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decreases G1- and G2-phase cells, but increases S-phase
population. In addition, IFN-α inhibited cyclin dependent
kinases (CDK), CDK2-, CDK3-, CDK4-, and cyclin Ebut not cyclin A-associated kinase activities and induced
cell cycle arrest in carcinoid tumor [58]. Thus, our data
suggests that expression of p21 is associated with the
tumor growth suppressive effect of IL-4.
STAT6 proteins that relay signals from activated
cytokine in the plasma membrane to the nucleus,
where they regulate gene transcription in the control of
cancer growth [59]. So, it alone can induce apoptosis.
Overexpression of mSTAT6 alone inhibited proliferation,
increased the basal rate of apoptosis, and inhibited focus
formation of MCF-7 human breast cancer cells [60].
STAT6 blockade by STAT6 siRNA and by anti-IL-4
inhibited IL-4-mediated apoptosis in HepG2 cells and in
human hepatocytes [12]. It was reported that activation
of STAT proteins is generally associated with tumor
tissues. But, STAT1 expression is lower in head and
neck tumor than normal tissue [61]. STAT3 is increased
in gastric [62] and breast tumor [63]. STAT4 is increased
in prostate tumor [64]. STAT6 is also increased in colon
[65], glioblastoma [66], breast [67], prostate tumor [64]
and melanoma compared to normal tissue. Cytokines
have antitumor effects through STAT mediated signaling
[68]. IL-12 activates STAT4 and enhances antitumor
activity through IFN-production [69]. IL-27 induced
activation of STAT1 enhances antitumor activity in
human epidermal keratinocytes [70]. Overexpressed IL-23
enhances antitumor activity in SU-DHL-4 human B cell
lymphoma cell inoculated xenograft model [71], however,
it is also regulated that endogenous IL-23 promotes
pro-tumor activity through STAT3 activation by inducing
inflammatory responses including IL-17 production [72].
It is also reported that IL-13 involved in the IL-4R-STAT6
pathway, are necessary for tumor promotion in 15-12RM
sarcoma model. Our data demonstrated that consistent with
cancer cell growth inhibition, IL-4 induced DNA binding
activity of STAT6 and nucleus phosphorylation of STAT6
were increased in a B16F10 melanoma cell and melanoma
tumor model. We also found higher expression of p21 as
well as STAT6 in human melanoma tissues compared
to normal skin tissues. It is also reported that STAT
proteins are related to p21-mediated apoptosis pathway.
Thrombin inhibits DU145 prostate cancer cell, MEF
murine fibroblast cell and CHRF human megakaryocyte
cell growth via up-regulation of p21 and capases via a p53
independent and STAT1 dependent pathway [32]. IFN-γ
induced up-regulation of p21 and activation of STAT1
protein in epithelial cell carcinoma [73] and ovarian cancer
cell lines [74]. IL-13/4 induces p21 expression in human
monocytes by an IL-13R/JAK pathway, through increased
p21 gene transcription, which is probably sustained by
the STAT responsive element, and that the activation of
PPARγ by this cytokine can counteract this induction [75].
Cancer cell growth-inhibitory effect of STAT6 was shown
www.impactjournals.com/oncotarget

to be mediated by induction of the G1 cyclin-dependent
kinase inhibitors p21Cip1/WAF1 and p27Kip1 in human breast
cancer cells. STAT6 knockdown resulted in enhanced cell
proliferation and a decrease in p21 and p27 mRNA levels
in the steroid-responsive and non-responsive T-47D and
MDA-MB-231 cell lines, respectively [76]. Moreover,
we found that the increment of STAT6 by IL-4 was also
abolished by the transfection with p21 siRNA both in
SK-MEL-28 and B16F10 cells. These data suggest that
the activation of STAT6 by IL-4 is mediated by p21
expression. Thus, our data suggest that IL-4 suppresses
tumor growth through p21-mediated activation of STAT6
in melanoma tumor of tissues.

MATERIALS AND METHODS
Materials
Recombinant human IL-4 and mouse IL-4 were
purchased from R & D system (Minneapolis, Minnesota).

Cell culture
SK-MEL-28 human melanoma cells were obtained
from the Korean Cell Line Bank (Seoul, Korea). B16F10
mouse melanoma cells, A549 and NCI-H460 human lung
cancer cells, SW480 and HCT116 human colon cancer
cells, Caki-1 and SN12C human renal cancer cells, Ca
Ski and C33A human cervical cancer cells, and MCF-7
and MDA-MB 231 human breast cancer cells were
obtained from the American Type Culture Collection
(Cryosite, Lane Cove NSW, Australia). A549, NCI-H460
and SW480 cells were grown in RPMI1640 (Gibco, Life
Technologies, Grand Island, NY) with 10 % fetal bovine
serum, 100 U/ml penicillin and 100 μg/ml streptomycin at
37°C in 5 % CO2 humidified atmosphere. B16F10, Caki-1,
SN12C, Ca Ski, C33A and MCF-7 cells were grown in
DMEM (Gibco, Life Technologies, Grand Island, NY)
with 10 % fetal bovine serum, 100 U/ml penicillin and
100 μg/ml streptomycin at 37°C in 5 % CO2 humidified
atmosphere. These cell lines were authenticated by
monitoring of cell morphology, contamination inspection.

Human samples
The human melanoma tissues and human normal
skin tissues samples were purchased from US Biomax, Inc.
cancer tissue bank collection (US Biomax, Inc., MD, USA).

Cell viability assay
Cells were plated in 96-well plates and
subsequently treated with IL-4 (0–50 ηg/mL) for 24 hr.
After treatment, cell growth was measured by MTT [3(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
Bromide] assay (Sigma Aldrich, St. Louis, MO) according
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Electro mobility shift assay

to the manufacturer’s instructions. Briefly, MTT (5 mg/ml)
was added and plates were incubated at 37°C for 2 hr
before 100 µl dimethyl sulfoxide (DMSO) was added to
each well. Finally, the absorbance of each well was read at
a wavelength of 540 nm using a microplate reader.

The DNA binding activity of STAT6 was
determined using an electrophoretic mobility shift assay
(EMSA) performed as according to the manufacturer’s
recommendations (Promega). In short, SK-MEL-28 and
B16F10 cells were cultured on 100-mm culture dishes.
After treatment with IL-4 (10, 25, 50 ng/ml) for 1 hr,
the cells were washed twice with PBS, followed by the
addition of 1 ml of PBS, and the cells were scraped into a
cold Eppendorf tube. Nuclear extracts were prepared and
processed for EMSA as previously described. The relative
densities of the DNA–protein binding bands were scanned
by densitometry using MyImage (SLB), and quantified by
Labworks 4.0 software (UVP, Inc., Upland, CA).

Evaluation of apoptotic cell death
TUNEL assay was performed by using the
DeadEndTM Fluorometric TUNEL System (Promega,
Madison, Wisconsin, USA) for in situ detection
of apoptotic cells, according to the manufacturer’s
instructions. B16F10 cells (1 × 104 cells/well) were
cultured on 8-chamber slides, after cells were treated
with IL-4. The cells and tumor tissues were washed with
PBS and fixed by incubation in 4% paraformaldehyde
in PBS for 1 hr at room temperature. Membrane was
permeabilized by exposure to 0.1% Triton X-100 in
PBS for 5 min at room temperature. For DAPI staining,
slides were incubated for 15 min at room temperature
in the dark with a mounting medium for fluorescence
containing DAPI (Vector Laboratories, Inc., Burlingame,
CA). The cells were then observed through a fluorescence
microscope (Leica Microsystems AG, Wetzlar, Germany).
The total number of cells in a given area was determined
by using DAPI and TUNEL staining. The apoptotic index
was determined as the number of DAPI-stained TUNELpositive cells divided by the total number of cells counted
× 100.

Transfection of siRNA
Human and murine melanoma cells (1 × 104
cells/well) were plated in 96-well plates and transiently
transfected with siRNA, using a mixture of siRNA and
the WellFect-EX PLUS reagent in OPTI-MEN, according
to the manufacturer’s specification (WelGENE, Seoul,
Korea). The transfected cells were treated with 50 ng/
ml IL-4 for 24 or 1 hr and then used for detecting cell
viability and protein expression (1 hr culture) and STAT6
and activation (1 hr culture).

Ethics statement
All animal experiments were approved and carried
out according to the Guide for the Care and Use of
Animals [Chungbuk National University Animal Care
Committee, Korea (CBNU-278-11-10)].

Western blotting
SK-MEL-28 cells and B16F10 cells treated with
IL-4 (0–50 ng/ml) for 24 hr were homogenized with
a protein extraction solution (PRO-PREPTM, Intron
Biotechnology), and lysed by 60 min incubation on ice.
The cell lysate was centrifuged at 15,000 rpm for 15 min
at 4°C. Equal amounts of protein (20 µg) were separated
on a SDS/12%-polyacrylamide gel, and then transferred
to a polyvinylidene difluoride (PVDF) membrane (GE
Water and Process Technologies, Trevose, PA, USA).
Blots were blocked for 1 h at room temperature with 5 %
(w/v) skim milk in Tris-Buffered Saline Tween-20 [TBST:
10 mM Tris (pH 8.0) and 150 mM NaCl solution containing
0.05 % Tween-20]. After a short washing in TBST, the
membranes were immunoblotted with the following
primary antibodies: caspase-3, caspase-9, caspase-8, Bcl-2,
p53 (1:1,000 dilutions; Cell Signaling, Beverly, MA) and
IL-4, IL-4Rα, JAK1, p-JAK1, STAT6, p-STAT6, Bax,
p21, (1:1,000 dilutions; Santa Cruz Biotechnology, Santa
Cruz, CA). The blots were performed using specific
antibodies followed by second antibodies and visualization
by a chemiluminescence (ECL) detection system.
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Animals
pIL/Luc/CNS-1 was constructed by cloning a human
IL-4 promoter with CNS-1 enhancer into pTransLucent
(Panomics, CA) harboring the firefly luciferase gene.
The pIL/Luc/CNS-1 plasmid was microinjected into the
male pronuclei of fertilized embryos obtained by crossing
C57BL/6 (female) mice with DBA/2 (male) mice. The
injected eggs were then transferred into the oviducts of a
female pseudopregnant HR-1 recipient. Large numbers of
IL-4/Luc/CNS-1 Tg mice were produced by mating IL-4/
Luc/CNS-1 Tg mice and HR-1 mice [77]. The transgene
was identified via DNA-PCR analysis of the genomic
DNA isolated from the tails of the 3-week-old founder
mice as described in elsewhere [78]. The 8 to 28 week-old
IL-4/Luc/CNS-1 Tg mice (IL-4 mice) used in this study
were kindly provided from the National Institute of
Food and Drug Safety Evaluation of the Korea FDA
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